联合瘢痕调节剂治疗增生性瘢痕与瘢痕疙瘩:系统综述
该系统综述分析了联合使用多种瘢痕调节剂治疗增生性瘢痕与瘢痕疙瘩的证据,发现多种联合方案较曲安奈德单药治疗疗效增加且不良事件更少或相似,其中曲安奈德联合5-氟尿嘧啶的证据最强且最一致;作者希望鼓励更多关于独特药物联合的研究。
要点
- 多种瘢痕调节剂联合方案较曲安奈德单药治疗显示疗效增加且不良事件更少或相似。
- 曲安奈德联合5-氟尿嘧啶在所有联合方案中证据最强且最一致。
- 目前这些病变尚无金标准治疗,联合治疗范式正在演变。
核心结论
- 许多联合方案显示较曲安奈德单药治疗疗效增加且不良事件更少或相似,其中曲安奈德联合5-氟尿嘧啶证据最强且最一致。
研究设计与样本
- 系统综述,旨在严格分析使用一种以上瘢痕调节剂的现有证据。
主要发现
- 许多联合方案显示较曲安奈德单药治疗疗效增加且不良事件更少或相似。
- 曲安奈德联合5-氟尿嘧啶在所有联合方案中显示最强且最一致的证据。
关键数值与推荐
- 将5-氟尿嘧啶、博来霉素或A型肉毒毒素加入曲安奈德单药治疗已成为治疗增生性瘢痕和瘢痕疙瘩的潜在药物组合。
临床怎么用
- 作者希望鼓励更多关于独特药物联合的研究,以可能改善有症状的增生性瘢痕或瘢痕疙瘩患者的结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Injury to the skin can cause abnormal wound healing and continuous inflammation that leads to the formation of hypertrophic scars and keloids. These lesions often cause significant negative impact on a patient's life due to aesthetic, physical, social, and psychological consequences. Numerous treatment modalities exist for these hypertrophic scars and keloids, which include silicone sheeting, pressure garments, intralesional injection/topical application of scar-modulating agents, laser therapy, and surgical excision. Due to increased efficacy, an evolving treatment paradigm encourages the use of multiple treatment modalities instead of one treatment modality. However, no gold standard treatment exists for these lesions, leaving many people with unsatisfactory results. Adding scar-modulating agents such as 5-Fluorouracil, bleomycin, or Botulinum Toxin A to triamcinolone monotherapy has emerged as a potential drug combination for treating hypertrophic scars and keloids. We sought to critically analyze the evidence that exists for the use of more than one scar-modulating agent. This was done by conducting a systematic review to determine the efficacy of these combined drug regimens. We found that many of these combinations show evidence of increased efficacy and fewer/similar adverse events to triamcinolone monotherapy. Triamcinolone and 5-Fluorouracil showed the strongest and most consistent evidence out of all combinations. With this review, we intend to encourage more research into unique drug combinations that may improve outcomes for patients with symptomatic hypertrophic scars or keloids.
引用
- Bernabe RM, Won P, Lin J, et al. Combining scar-modulating agents for the treatment of hypertrophic scars and keloids: A systematic review. J Plast Reconstr Aesthet Surg. 2023. PMID: 37979279. doi:10.1016/j.bjps.2023.10.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。